Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short term Debt: 2016-2023

Historic Short term Debt for Cartesian Therapeutics (RNAC) over the last 6 years, with Dec 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Short term Debt rose 233.97% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 233.97%. This contributed to the annual value of $28.3 million for FY2023, which is 233.97% up from last year.
  • Cartesian Therapeutics' Short term Debt amounted to $28.3 million in FY2023, which was up 233.97% from $8.5 million recorded in FY2022.
  • Over the past 5 years, Cartesian Therapeutics' Short term Debt peaked at $28.3 million during FY2023, and registered a low of $6.0 million during FY2021.
  • Over the past 3 years, Cartesian Therapeutics' median Short term Debt value was $8.5 million (recorded in 2022), while the average stood at $14.2 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Short term Debt fell by 11.60% in 2019, and later soared by 233.97% in 2023.
  • Yearly analysis of 4 years shows Cartesian Therapeutics' Short term Debt stood at $18.9 million in 2019, then reached $6.0 million in 2021, then skyrocketed by 42.19% to $8.5 million in 2022, then surged by 233.97% to $28.3 million in 2023.